Hims & Hers is an increasingly profitable, vertically integrated telehealth platform with major tailwinds, positioning it as ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

Andrew Dudum; Chairman of the Board, Chief Executive Officer; Hims & Hers Health Inc Oluyemi Okupe; Chief Financial Officer; Hims & Hers Health Inc Good afternoon, ladies and gentlemen. Thank you for ...

Hims & Hers' first-quarter 2025 performance reflects continued strength in its online revenue channel on the back of solid ...

Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven ...

Hims & Hers registered revenues ... Marketing expenses jumped 77.1% year over year to $231.2 million, while technology and development expenses increased 95.2% year over year to $29.9 million.

The companies will sell the drug at a reduced price of $499 a month ... example, Hims will charge $100 for the monthly subscription, which also includes a monthly tele-visit with a healthcare provider ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...